Key result
Shugan Jieyu capsule will be evaluated for its efficacy and safety in treating essential hypertension with insomnia, anxiety, or depression in this systematic review and meta-analysis protocol.
Why the study?
Despite clinical trials of Shugan Jieyu capsule for essential hypertension with insomnia, anxiety, or depression, the lack of a systematic review and meta-analysis has not provided effective evidence.
Does Shugan Jieyu capsule added to routine antihypertensive drugs improve blood pressure and concomitant symptoms in patients with essential hypertension and insomnia, anxiety, or depression?
Systematic Review
Does Shugan Jieyu capsule added to routine antihypertensive drugs improve blood pressure and concomitant symptoms in patients with essential hypertension and insomnia, anxiety, or depression?
This protocol outlines a systematic review and meta-analysis to evaluate the efficacy and safety of Shugan Jieyu capsule combined with conventional antihypertensives for essential hypertension accompanied by insomnia, anxiety, or depression.
Should not change practice yet; leaves open whether SJC improves BP or symptoms until the planned review reports.
BACKGROUND: Shugan Jieyu capsule can reduce blood pressure and improve its concomitant symptoms. However, it is not widely used in clinic because of its incomplete understanding of its nature. There are many reports on the clinical trials of Shugan Jieyu capsule in the treatment of essential hypertension with insomnia, anxiety or depression in recent years. However, the lack of systematic review and meta-analysis has not provided effective evidence. As a consequence, we provide a protocol to evaluate the efficacy and safety of Shugan Jieyu capsule (SJC) in the treatment of essential hypertension (EH) with insomnia, anxiety or depression. METHODS: The search time range of Cochrane Library, PubMed, excerpt Database (EMBASE), Chinese Biomedical Literature Database (CBM), China National knowledge Infrastructure (CNKI), Chinese Science and Technology Journal Database (VIP), and Wanfang Database (WanFang), was searched by computer from the establishment of the database to December 31, 2020. In the meanwhile, the list of references and related reviews were checked. The data were extracted by 2 evaluators independently, and the literature quality was evaluated according to Cochrane manual 4.2.2. In addition, CochraneRevman5.3 software was used for heterogeneity test, meta-analysis, publication bias analysis and GRADE3.6 evidence quality classification system evaluation related statistical data. RESULTS: This study intends to evaluate the efficacy and safety of SJC in the treatment of EH from many aspects, including changes in blood pressure [systolic blood pressure (SBP), diastolic blood pressure (DBP)], effective rate of blood pressure reduction, improvement rate of concomitant symptoms and adverse reactions. CONCLUSION: The conclusion of systematic review intends to provide evidence for judging that SJC is an effective intervention for EH patients with insomnia, anxiety and depression. PROSPERO REGISTRATION NUMBER: PROSPERO CRD 42021219704.
No takes yet. Share an insight, caveat, or question.
Fan et al. (2021) conducted a systematic review in Essential hypertension with insomnia, anxiety or depression. Shugan Jieyu capsule vs. Conventional antihypertensive drugs with or without placebo was evaluated on Changes in blood pressure (SBP, DBP), effective rate of blood pressure reduction, and improvement rate of concomitant symptoms. Shugan Jieyu capsule will be evaluated for its efficacy and safety in treating essential hypertension with insomnia, anxiety, or depression in this systematic review and meta-analysis protocol.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: